Investor's Business Daily on MSN14h
ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?
ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst remained upbeat on the "mega trends" driving the CPAP maker.Please watch the video ...
HME News18h
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
MassDevice19h
ResMed revenue up 10% in Q2 — but GLP-1 questions remain
ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...
About half of Americans approve of using weight-loss drugs to treat obesity, AP-NORC poll finds
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...
Top 20 biopharma companies’ market caps rise 1.7% over 2024 amid policy
Eli Lilly achieved the largest market capitalisation growth of 32.4% to $733bn in 2024, driven by strong demand for Mounjaro ...
How GLP-1 medications are transforming diabetes and weight loss treatment
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...